Hims & Hers Draws Blood In Lab Testing Battle, Stock Up 558%
Skip the waiting room — Hims & Hers just turned your living room into a lab. The telehealth disruptor snatched up Trybe Labs Wednesday, adding FDA-cleared at-home blood testing to its arsenal. Following its GLP-1 release and controversial Super Bowl ad, the move aims to tackle a critical healthcare barrier head-on — sending soaring 20% to record highs.
- The acquisition expands Hims’ testing capabilities to include hormone levels, cardiac risk, stress markers, liver function, and prostate health — with rollout planned over the next year.
- Users will receive a blood lancet device that attaches to the upper arm and collects whole blood samples with a single button press — leveraging anonymized blood work data to accelerate its MedMatch AI platform.
There will be blood: Hims & Hers’ leap into at-home testing plugs a critical gap in its end-to-end ecosystem — which spans prescriptions, skincare, supplements, and telehealth consultations. By integrating lab data, the company aims to “deepen insights” for personalized patient care. With profitable operations and a 558.5% one-year stock surge, this latest venture isn’t about stopping the bleeding — it’s about giving legacy healthcare a taste of its own medicine.
